OriCiro Genomics
Edit

OriCiro Genomics

https://www.oriciro.com/
Last activity: 10.07.2026
Active
Categories: AgriTechDevelopmentDiagnosticsFoodTechIndustryITMedtechResearchTechnologyTools
OriCiro is focused on the development and commercialization of cell-free synthesis and amplification technology of genome-scale large DNA for applications in gene and cell-based therapies and synthetic biolog
Likes
1
Mentions
8
Location: Japan, Tokyo
Total raised: $9.15M
Founded date: 2018

Investors 3

Funding Rounds 1

DateSeriesAmountInvestors
17.08.2021Series B$9.15M-

Mentions in press and media 8

DateTitleDescription
06.06.2022OriCiro Announces Series B2 Financing to Advance Cell-Free DNA Technology for Innovative Therapeutics and Synthetic BiologyTOKYO, June 6, 2022 /PRNewswire/ -- OriCiro Genomics, a pioneer in cell-free synthesis and amplification of genome-scale large DNA for advanced therapy and synthetic biology, today announced that it has closed Series B2 financing from Asahi...
18.05.2022OriCiro Genomics expand into Boston, Open new office in North AmericaTOKYO, May 18, 2022 /PRNewswire/ -- OriCiro Genomics K.K. a pioneer in cell-free synthesis and amplification of genome-scale large DNA for advanced therapeutics and synthetic biology, today announced the open US office in North America. In ...
29.11.2021OriCiro Genomics Launches New enzymatic DNA synthesis tool for commonly used vectorsTOKYO, Nov. 29, 2021 /PRNewswire/ -- OriCiro Genomics Inc., a pioneer in cell-free synthesis and amplification of genome-scale large DNA for advanced therapeutics and synthetic biology, today announced the launch of OriCiro® Cell-Free Switc...
23.07.2021OriCiro Genomics Raises ¥800M in Series B FinancingOriCiro Genomics, a Tokyo, Japan-based pioneer in cell-free synthesis and amplification of genome-scale large DNA for advanced therapy and synthetic biology, raised ¥800m in Series B financing. The round was led by The University of Tokyo E...
20.07.2021OriCiro Announces ¥1 Billion Series B Financing to Advance Cell-Free DNA Technology for Innovative Therapeutics and Synthetic BiologyTOKYO, July 20, 2021 /PRNewswire/ -- OriCiro Genomics, a pioneer in cell-free synthesis and amplification of genome-scale large DNA for advanced therapy and synthetic biology, today announced that it has raised ¥800 million in Series B fina...
20.07.2021OriCiro Announces ¥1 Billion Series B Financing to Advance Cell-Free DNA Technology for Innovative Therapeutics and Synthetic BiologyTOKYO, July 20, 2021 /PRNewswire/ -- OriCiro Genomics, a pioneer in cell-free synthesis and amplification of genome-scale large DNA for advanced therapy and synthetic biology, today announced that it has raised ¥800 million in Series B fina...
20.07.2021OriCiro Announces ¥1 Billion Series B Financing to Advance Cell-Free DNA Technology for Innovative Therapeutics and Synthetic Biology
30.09.2020OriCiro Launches World's First Cell-Free Amplification Technology for Large Circular DNA

Reviews 0

Sign up to leave a review

Sign up Log In